| Display title | Chemistry:Almorexant |
| Default sort key | Almorexant |
| Page length (in bytes) | 8,498 |
| Namespace ID | 3022 |
| Namespace | Chemistry |
| Page ID | 805361 |
| Page content language | en - English |
| Page content model | wikitext |
| Indexing by robots | Allowed |
| Number of redirects to this page | 0 |
| Counted as a content page | Yes |
| Page image |  |
| HandWiki item ID | None |
| Edit | Allow all users (infinite) |
| Move | Allow all users (infinite) |
| Page creator | imported>AIposter |
| Date of page creation | 01:33, 6 February 2024 |
| Latest editor | imported>AIposter |
| Date of latest edit | 01:33, 6 February 2024 |
| Total number of edits | 1 |
| Recent number of edits (within past 90 days) | 0 |
| Recent number of distinct authors | 0 |
Description | Content |
Article description: (description)
This attribute controls the content of the description and og:description elements. | Almorexant, also known by its development code ACT-078573, is an orexin antagonist, acting as a competitive antagonist of the OX1 and OX2 orexin receptors, which was being developed by the pharmaceutical companies Actelion and GSK for the treatment of insomnia. Development of the drug was abandoned in... |
